Maureen Kenny
Executive Editor at Pharma Intelligence
Executive editor at Informa Pharma Intelligence (Pink Sheet). All opinions are my own.
Articles
-
Oct 19, 2024 |
insights.citeline.com | Maureen Kenny
Gilead's Biktarvy Set For EU Approval 30 Apr 2018 • By Maureen KennyA combination therapy – Gilead Science’s Biktarvy – a hybrid medicine and a generic can look forward to EU approval after getting the OK from the EMA’s drug evaluation committee last week. Gilead's new HIV combination has been recommended for EU approval
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 2K
- DMs Open
- No
Novartis Restructure: With top names departing, refocused therapeutic priorities & new targets set, this @PharmaScrip article by @awmcconaghie is important reading for all in the industry, from biotech partners (and would-be partners) to big pharma peers. https://t.co/ZwokWkevMQ
Alexander Natz of @EUCOPE explains in this @PharmaPinkSheet article the new EU regulation on health technology assessment, one of the biggest developments to affect the pharma industry in over a decade. https://t.co/h31VR0HU1u
RT @DIA_Europe: Welcome to #DIAEurope2022 ! #Day1 we are so excited to be face-to-face in Brussels! Our three-day event is just beginning…
